Video Experimental Relacionado

Updated: Jul 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Más allá del laboratorio: implicaciones clínicas para la pleiotropía de las estatinas

Julian P J Halcox¹, John E Deanfield

¹Vascular Physiology Unit, Department of Cardiology, Institute of Child Health, University College London, London, England.

|June 3, 2004

Resumen

Las estatinas, o los inhibidores de la reductasa de la 3-hidroxi-3-metilglutaril-coenzima A, ofrecen beneficios más allá de la reducción de los lípidos. La evidencia actual sugiere que la reducción del colesterol sigue siendo el principal impulsor de su eficacia clínica.

Área de la Ciencia:

Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
Farmacología Farmacología.
Investigación de la aterosclerosis Investigación de la aterosclerosis.

Sus antecedentes:

Los inhibidores de la reductasa (estatinas) de la 3-hidroxi-3-metilglutaril-coenzima A (HMG-CoA) han revolucionado el manejo de la aterosclerosis.
Las estatinas afectan los niveles de lípidos e influyen en las vías inflamatorias, oxidativas y trombóticas.
Estos efectos pleiotrópicos pueden contribuir a los beneficios clínicos observados más allá de la modificación de los lípidos.

Objetivo del estudio:

Revisar la evidencia clínica de los beneficios de las estatinas independientemente de los efectos reductores de lípidos.
Para explorar la utilidad de las estatinas en condiciones no típicamente relacionadas con el colesterol alto.
Para evaluar si los beneficios preceden a los cambios en el nivel de lípidos y si la magnitud es independiente del colesterol.

Principales métodos:

Revisión de los datos de ensayos clínicos y la literatura científica.
Análisis de la evidencia que examina los efectos pleiotrópicos de las estatinas.
Evaluación de la relación entre los resultados clínicos y la reducción de lípidos.

Principales resultados:

Si bien las estatinas poseen efectos pleiotrópicos, la reducción de las lipoproteínas de baja densidad (LDL) se considera actualmente el mecanismo principal para los beneficios clínicos.
La evidencia de beneficios clínicos significativos independientes de la reducción de LDL es limitada.
La magnitud del beneficio clínico generalmente se correlaciona con el grado de reducción del colesterol LDL.

Conclusiones:

La reducción de las lipoproteínas de baja densidad sigue siendo el principal mecanismo que impulsa los beneficios clínicos del tratamiento con estatinas.
La terapia con estatinas debe continuar enfocándose en la reducción de lípidos para la mitigación del riesgo cardiovascular.
Investigaciones adicionales pueden aclarar el papel y el alcance de los efectos pleiotrópicos en contextos específicos.

Más Videos Relacionados

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Videos de Conceptos Relacionados

Pleiotropy

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...